Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Brain ; 13(1): 147, 2020 11 13.
Article in English | MEDLINE | ID: mdl-33183323

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline with accumulation of amyloid beta (Aß) and neurofibrillary tangles that usually begins 15-30 years before clinical diagnosis. Rodent models that recapitulate aggressive Aß and/or the pathology of neurofibrillary tangles are essential for AD research. Accordingly, non-invasive early detection systems in these animal models are required to evaluate the phenotypic changes, elucidate the mechanism of disease progression, and facilitate development of novel therapeutic approaches. Although many behavioral tests efficiently reveal cognitive impairments at the later stage of the disease in AD models, it has been challenging to detect such impairments at the early stage. To address this issue, we subjected 4-6-month-old male AppNL-G-F/NL-G-F knock-in (App-KI) mice to touchscreen-based location discrimination (LD), different object-location paired-associate learning (dPAL), and reversal learning tests, and compared the results with those of the classical Morris water maze test. These tests are mainly dependent on the brain regions prone to Aß accumulation at the earliest stages of the disease. At 4-6 months, considered to represent the early stage of disease when mice exhibit initial deposition of Aß and slight gliosis, the classical Morris water maze test revealed no difference between groups, whereas touchscreen-based LD and dPAL tasks revealed significant impairments in task performance. Our report is the first to confirm that a systematic touchscreen-based behavioral test battery can sensitively detect the early stage of cognitive decline in an AD-linked App-KI mouse model. This system could be applied in future translational research.


Subject(s)
Alzheimer Disease/complications , Amyloid beta-Protein Precursor/metabolism , Cognitive Dysfunction/complications , Discrimination Learning , Gene Knock-In Techniques , Paired-Associate Learning , Task Performance and Analysis , Alzheimer Disease/physiopathology , Animals , Astrocytes/pathology , Cognitive Dysfunction/physiopathology , Disease Models, Animal , Maze Learning , Mice, Inbred C57BL , Mice, Transgenic , Microglia/pathology , Neurogenesis , Neuroglia/metabolism , Neuroglia/pathology , Plaque, Amyloid/complications , Plaque, Amyloid/pathology , Spatial Memory
2.
Behav Brain Res ; 359: 942-949, 2019 02 01.
Article in English | MEDLINE | ID: mdl-29935275

ABSTRACT

Psychological stresses such as social loss and separation during childhood induce hardship, referred to as emotional pain. These experiences are well-documented risk factors for the development of physical pain in adulthood. However, the underlying neuronal mechanisms of this exacerbation of pain are largely unknown, and consequently there is no effective pharmacotherapy. In this study, we sought to determine whether infant maternal separation (MS) contributes to aggravation of neuropathic pain in adult mice. MS increased anxiety- and depression-like behavioral responses to adult stress. In MS animals, chronic constriction injury (CCI) heightened the sensory dimension of chronic pain relative to that of control mice. However, MS mice treated with fluoxetine for 4 weeks after MS did not exhibit augmentation of allodynia, and their emotional response was attenuated. Microglia were more abundant in the spinal cord in MS/CCI mice than in control/CCI mice. These results suggest that emotional impairment is related to augmentation of neuropathic pain, and that dysfunction of microglial activation contributes to heightened pain sensitivity.


Subject(s)
Maternal Deprivation , Mood Disorders/etiology , Neuralgia/complications , Neuralgia/psychology , Animals , Animals, Newborn , Antidepressive Agents, Second-Generation/therapeutic use , Calcium-Binding Proteins , Disease Models, Animal , Fluoxetine/therapeutic use , Food Preferences/drug effects , Glial Fibrillary Acidic Protein/metabolism , Hyperalgesia/physiopathology , Male , Maze Learning/drug effects , Mice , Mice, Inbred ICR , Microfilament Proteins , Microglia/metabolism , Mood Disorders/drug therapy , Mood Disorders/pathology , Spinal Cord/drug effects , Spinal Cord/pathology , Sucrose/administration & dosage , Swimming/psychology
3.
Behav Brain Res ; 359: 935-941, 2019 02 01.
Article in English | MEDLINE | ID: mdl-29935276

ABSTRACT

Patients suffering from neuropsychiatric disorders such as substance use and addiction disorders show impaired decision-making, which may be associated with their psychiatric disorders. Previously, using a gambling test for rodents, we demonstrated that methamphetamine-dependent rats showed alterations in their decision-making strategy. In this study, we investigated the effect of nicotine on impaired decision-making strategy in rats which have been treated repeatedly with methamphetamine. Nicotine has previously been shown to have therapeutic effects on attentional and cognitive abnormalities in psychosis. Rats were administered methamphetamine subcutaneously (sc) at 4 mg/kg once a day, for 30 days, and their decision-making was then assessed with a rodent gambling task. We found that methamphetamine-treated rats preferred the high-risk/high-return actions, which is consistent with our previous findings. Methamphetamine-induced impairment of decision-making was reversed by daily nicotine treatment (0.3 mg/kg, sc). This effect was associated with the reduction of lose-shift behavior after negative reward prediction error. Repeated treatment with nicotine had no effects on arm-choice behavior in naïve rats. Varenicline, an α4ß2-nicotinic acetylcholine receptor partial agonist, also ameliorated the altered decision-making in methamphetamine-treated rats. Our findings suggest that nicotine treatment is useful for ameliorating the altered decision-making caused by methamphetamine treatment, and that the α4ß2-nicotinic acetylcholine receptor is a therapeutic target for poor decision-making.


Subject(s)
Decision Making/drug effects , Nicotine/pharmacology , Nicotinic Agonists/pharmacology , Reward , Varenicline/pharmacology , Animals , Central Nervous System Stimulants/pharmacology , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Male , Methamphetamine/pharmacology , Rats , Rats, Wistar , Risk-Taking , Time Factors
4.
J Am Soc Nephrol ; 27(3): 766-80, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26376860

ABSTRACT

Hyponatremia is the most common clinical electrolyte disorder. Once thought to be asymptomatic in response to adaptation by the brain, recent evidence suggests that chronic hyponatremia may be linked to attention deficits, gait disturbances, risk of falls, and cognitive impairments. Such neurologic defects are associated with a reduction in quality of life and may be a significant cause of mortality. However, because underlying diseases such as adrenal insufficiency, heart failure, liver cirrhosis, and cancer may also affect brain function, the contribution of hyponatremia alone to neurologic manifestations and the underlying mechanisms remain unclear. Using a syndrome of inappropriate secretion of antidiuretic hormone rat model, we show here that sustained reduction of serum sodium ion concentration induced gait disturbances; facilitated the extinction of a contextual fear memory; caused cognitive impairment in a novel object recognition test; and impaired long-term potentiation at hippocampal CA3-CA1 synapses. In vivo microdialysis revealed an elevated extracellular glutamate concentration in the hippocampus of chronically hyponatremic rats. A sustained low extracellular sodium ion concentration also decreased glutamate uptake by primary astrocyte cultures, suggesting an underlying mechanism of impaired long-term potentiation. Furthermore, gait and memory performances of corrected hyponatremic rats were equivalent to those of control rats. Thus, these results suggest chronic hyponatremia in humans may cause gait disturbance and cognitive impairment, but these abnormalities are reversible and careful correction of this condition may improve quality of life and reduce mortality.


Subject(s)
Gait Disorders, Neurologic/etiology , Hyponatremia/complications , Inappropriate ADH Syndrome/physiopathology , Memory Disorders/etiology , Animals , Astrocytes/drug effects , Astrocytes/metabolism , CA1 Region, Hippocampal/physiopathology , CA3 Region, Hippocampal/physiopathology , Cells, Cultured , Chronic Disease , Cognition Disorders/blood , Cognition Disorders/etiology , Disease Models, Animal , Fear/physiology , Gait Disorders, Neurologic/blood , Glutamic Acid/metabolism , Hyponatremia/blood , Hyponatremia/psychology , Inappropriate ADH Syndrome/complications , Inappropriate ADH Syndrome/psychology , Male , Memory Disorders/blood , Microdialysis , Neuronal Plasticity , Rats , Rats, Sprague-Dawley , Sodium/blood , Sodium/pharmacology , Synapses/physiology
5.
Proc Natl Acad Sci U S A ; 112(29): E3930-9, 2015 Jul 21.
Article in English | MEDLINE | ID: mdl-26150496

ABSTRACT

Patients suffering from neuropsychiatric disorders such as substance-related and addictive disorders exhibit altered decision-making patterns, which may be associated with their behavioral abnormalities. However, the neuronal mechanisms underlying such impairments are largely unknown. Using a gambling test, we demonstrated that methamphetamine (METH)-treated rats chose a high-risk/high-reward option more frequently and assigned higher value to high returns than control rats, suggestive of changes in decision-making choice strategy. Immunohistochemical analysis following the gambling test revealed aberrant activation of the insular cortex (INS) and nucleus accumbens in METH-treated animals. Pharmacological studies, together with in vivo microdialysis, showed that the insular neural system played a crucial role in decision-making. Moreover, manipulation of INS activation using designer receptor exclusively activated by designer drug technology resulted in alterations to decision-making. Our findings suggest that the INS is a critical region involved in decision-making and that insular neural dysfunction results in risk-taking behaviors associated with altered decision-making.


Subject(s)
Cerebral Cortex/physiology , Decision Making , Methamphetamine/administration & dosage , Animals , Behavior, Animal , Choice Behavior , Gambling , Male , Maze Learning , Motivation , Proto-Oncogene Proteins c-fos/metabolism , Rats, Wistar , Reinforcement, Psychology , Reward , Risk-Taking , Synaptic Transmission , gamma-Aminobutyric Acid/metabolism
6.
PLoS One ; 9(7): e103458, 2014.
Article in English | MEDLINE | ID: mdl-25062013

ABSTRACT

Soluble oligomeric amyloid ß (oAß) causes synaptic dysfunction and neuronal cell death, which are involved in the pathogenesis of Alzheimer's disease (AD). The hematopoietic growth factor granulocyte-colony stimulating factor (G-CSF) is expressed in the central nervous system (CNS) and drives neurogenesis. Here we show that G-CSF attenuated oAß neurotoxicity through the enhancement of the enzymatic activity of Aß-degrading enzyme neprilysin (NEP) in neurons, while the NEP inhibitor thiorphan abolished the neuroprotection. Inhibition of MEK5/ERK5, a major downstream effector of G-CSF signaling, also ablated neuroprotective effect of G-CSF. Furthermore, intracerebroventricular administration of G-CSF enhanced NEP enzymatic activity and clearance of Aß in APP/PS1 transgenic mice. Thus, we propose that G-CSF may be a possible therapeutic strategy against AD.


Subject(s)
Amyloid beta-Peptides/toxicity , Granulocyte Colony-Stimulating Factor/pharmacology , Neprilysin/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Animals , Cells, Cultured , Humans , MAP Kinase Kinase 5/metabolism , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinase 7/metabolism , Neprilysin/antagonists & inhibitors , Neurons/metabolism , Thiorphan/pharmacology
7.
Behav Brain Res ; 268: 88-93, 2014 Jul 15.
Article in English | MEDLINE | ID: mdl-24713151

ABSTRACT

Alzheimer's disease is a progressive neurodegenerative disorder. Amyloid ß, a neurotoxic protein, causes disruption of hippocampal synaptic plasticity, and induces cognitive impairment in Alzheimer's disease. We previously revealed that fingolimod, a new oral immunosuppressant used to treat multiple sclerosis, ameliorates oligomeric amyloid ß-induced neuronal damage via up-regulation of neuronal brain-derived neurotrophic factor (BDNF). Here, we showed that oral administration of fingolimod ameliorated the impairment in object recognition memory and associative learning in mice injected with amyloid ß. This effect was associated with restoration of normal BDNF expression levels in the cerebral cortices and hippocampi, suggesting that neuroprotection was mediated by up-regulation of neuronal BDNF levels. Therefore, fingolimod may provide therapeutic effects in patients with Alzheimer's disease.


Subject(s)
Amyloid beta-Peptides/toxicity , Brain-Derived Neurotrophic Factor/metabolism , Brain/drug effects , Memory Disorders/drug therapy , Neuroprotective Agents/pharmacology , Peptide Fragments/toxicity , Propylene Glycols/pharmacology , Sphingosine/analogs & derivatives , Alzheimer Disease , Animals , Association Learning/drug effects , Association Learning/physiology , Brain/physiopathology , Cerebral Cortex/drug effects , Cerebral Cortex/physiopathology , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Fingolimod Hydrochloride , Hippocampus/drug effects , Hippocampus/physiopathology , Male , Memory Disorders/etiology , Memory Disorders/physiopathology , Mice, Inbred C57BL , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Sphingosine/pharmacology , Up-Regulation
8.
Behav Processes ; 103: 218-27, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24412730

ABSTRACT

We trained rats in a context discrimination paradigm by pairing a sucrose solution with lithium chloride in one context (conditioning context) and simple exposure to the same fluid in a second (neutral) context to establish a context-dependent aversion to the conditioned fluid. We then investigated whether transfer of the context dependency to a test fluid (a sodium chloride solution) was affected by two post-discrimination training treatments, an extended context discrimination training, and non-reinforced exposure to the conditioning context (context extinction). We found that the context-dependent flavor aversion that had been specific to sucrose transferred to the test fluid after the extensive training (Experiment 1). Context extinction eliminated the transfer effect that had been observed immediately after the context discrimination training (Experiment 2). In addition, an aversion acquired by sucrose through a simple conditioning of sucrose-LiCl pairings did not generalize to the test fluid (Experiment 3). These results emphasize the importance of a Pavlovian excitatory association between the conditioning context and nausea as a primary source of transfer of the context dependency, rather than a generalization of aversion acquired by the conditioned fluid to the test fluid.


Subject(s)
Avoidance Learning/physiology , Conditioning, Operant/physiology , Discrimination Learning/physiology , Extinction, Psychological/physiology , Taste/physiology , Animals , Cues , Lithium Chloride/pharmacology , Male , Nausea/chemically induced , Nausea/psychology , Rats , Rats, Wistar , Reinforcement, Psychology , Sodium Chloride/pharmacology , Sucrose/pharmacology , Sweetening Agents/pharmacology , Transfer, Psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...